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Purpose: The present study aims to investigate whether the combination treatment of 
 cordycepin (an extracted pure compound from Cordyceps sinensis) and cisplatin (a platinum-
based chemotherapy drug) has better apoptotic effect in head and neck squamous cell carcinoma 
(HNSCC).
Methods: The apoptotic influences of cordycepin and/or cisplatin treatments to human OC3, 
OEC-M1, and FaDu HNSCC cells were investigated by morphological observations, viability 
assay, flow cytometry assay, and Western blotting methods.
Results: Data showed that the cell death phenomenon increased as the dosage of cordycepin or 
cisplatin increased, and it appeared more in cordycepin plus cisplatin cotreatment among three 
cell lines. Cell survival rates significantly decreased as the dosage of cordycepin or cisplatin 
increased, and the better apoptotic effects were observed in cotreatment. Cell cycle analysis 
further demonstrated that percentages of subG1 cells in cordycepin or cisplatin treatments 
significantly increased, suggesting that cells underwent apoptosis, and cordycepin plus cispla-
tin induced many more subG1 cells. Furthermore, cordycepin or cisplatin induced caspase-8, 
caspase-9, caspase-3, and poly adenosine diphosphate-ribose polymerase protein cleavages, and 
stimulated c-Jun NH2-terminal kinase, extracellular signal-regulated kinase, and p38 protein 
phosphorylations. Moreover, cordycepin plus cisplatin cotreatment significantly activated those 
proteins with much better effects among three cell lines.
Conclusion: Cordycepin plus cisplatin have better apoptotic effect by activating caspase 
activation with possible MAPK pathway involvement in HNSCC cells.
Keywords: cordycepin, cisplatin, apoptosis, caspase, MAPK, HNSCC
Introduction
Betel quid-related oral cavity cancer is a unique type of head and neck squamous cell 
carcinoma (HNSCC) that occurs with an areca nut chewing habit, which is endemic 
in many areas around the world.1 In Taiwan, there are over 2,000 deaths in oral cav-
ity cancer yearly, and it is still increasing.2 Surgery and radiation are often used to 
treat local advanced HNSCC,3 but these treatments would damage a patient’s face 
and affect his or her salivary secretion and taste functions. For late-staged patients, 
chemotherapy is often used in combination with surgery and/or radiotherapy in order 
to improve the poor survival rate.4 The addition of platinum-based chemotherapy, 
such as cisplatin (cis-DDP) or carboplatin (CBDCA), is the major agent in HNSCC 
treatment.5 Cisplatin is the most efficient agent used to treat HNSCC; however, the 
development of cisplatin-resistance is the major limitation of treatment.6 Studies have 
shown the possible mechanisms involved in cisplatin resistance, including the reduc-
tion of intracellular accumulation of the chemotherapy drug, the down-regulation of 
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proapoptotic proteins, the increase of glutathione, and the 
upregulation of antiapoptotic proteins.7
Cordycepin, a pure extracted compound of Cordyceps 
sinensis, has been shown to have antitumor properties as 
it activates cysteine aspartic-specific protease (caspase) 
pathways.8,9 It is reported that cordycepin could inhibit the 
formation of polyadenylate polymerase or inactivate mes-
senger ribonucleic acid (RNA) polyadenylation to induce 
tumor cell apoptosis,10 which is characterized by cellular 
rounding-up, cytoplasmic contraction, plasma membrane 
blebbing, chromatin condensation, and deoxyribonucleic 
acid (DNA) fragmentation.11 During the course of apoptosis, 
the activation of caspases is commonly thought to be one of 
the earliest points in the no-return pathway of apoptosis.12 
In general, caspase can be divided into two groups: initiator 
caspases (including caspase-8, caspase-9, and caspase-10) 
and effector caspases (including caspase-3, caspase-6, and 
caspase-7). Initiator caspases are responsible for cleaving and 
activating effector caspases.13 The cleavage of caspases, such 
as caspase-7 and caspase-3, could be activated, which will 
further cleave poly adenosine diphosphate-ribose polymerase 
(PARP), which is responsible for DNA repair,12 and result in 
the execution of cell death.14
Besides caspase cascades, mitogen-activated protein 
kinases (MAPKs) are also involved in apoptosis regulation.15 
MAPKs consist of three family membranes: extracellular 
signal-regulated kinase (ERK), c-Jun NH2-terminal kinase 
(JNK), and p38 proteins.16 Studies have been reported that 
stress signals can activate the stress-activated protein kinases/
JNK protein kinases, which mediate cellular steps in the 
apoptosis of some cell types.17,18 It has been shown that ERK 
is response to growth stimuli is the important signal for anti-
apoptosis;16 however, the involvement of p38 in apoptosis is 
diverse. Phosphorylation of p38 can be initiated by MKK3 
and MKK6 at the threonine and tyrosine regions, which 
control many transcriptional factors and kinases to enhance 
cell survival or prompt apoptosis.16 Accordingly, caspase and 
MAPKs pathways may play important roles in the apoptosis 
of tumor cells activated by chemotherapy agents.
Cordycepin and cisplatin both have antitumor effects.6,8,9,19 
Thus, the attempt to clarify the combined effect of cisplatin 
plus cordycepin on HNSCC cell death in addition to an 
investigation of the underlying mechanisms is being con-
ducted in the present study. Three cell lines, OC3, OEC-M1, 
and FaDu cells, were used in the investigation. It should be 
noted that better effects in OC3, OEC-M1, and FaDu cells 
on apoptosis by cordycepin plus cisplatin were observed. 
These findings could encourage the development of more 
effective chemotherapy agents with different concomitant 
administration against betel nut-induced oral cancers.
Materials and methods
Chemicals
Cordycepin, cisplatin, penicillin-streptomycin, methylthiazol 
tetrazolium (MTT), dimethyltetrazolium bromide (DMSO), 
ribonuclease A, and propidium iodine (PI) were purchased 
from Sigma-Aldrich (St Louis, MO, USA). Fetal bovine 
serum, Dulbecco’s Modified Eagle’s Medium (DMEM), and 
Keratinocyte-SFM medium were purchased from Gibco® 
(Life Technologies, Carlsbad, CA, USA). Sodium hydroxide 
was purchased from Merck KGaA (Darmstadt, Germany). 
In addition, (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid) (HEPES) was purchased from Mallinckrodt Baker, 
Inc, (Phillipsburg, NJ, USA). Sodium bicarbonate, sodium 
carbonate, and sodium chloride were purchased from Riedel 
der Haen (Seelze, Germany). Fetal bovine serum, Roswell 
Park Memorial Institute 1640 medium, and lyophilized 
trypsin-ethylenediaminetetraacetic acid were purchased from 
Gibco® (Life Technologies). Tween 20, sodium hydroxide, 
and hydrochloric acid were purchased from Merck KGaA. 
Sodium dodecyl sulfate (SDS) and acrylamine, as well as 
Tris (base) were purchased from JT Baker® (AvantorTM 
Performance Materials, Phillipsburg, NJ, USA). Antibodies 
against cleaved caspase-8, caspase-9, caspase-3, and 
β-actin, as well as antibodies against phosphorylated-JNK, 
phosphorylated-ERK, and phosphorylated-p38 were pur-
chased from Cell Signaling Technology, Inc, (Beverly, MA, 
USA). Anti-PARP antibody was purchased from Oncogene 
Research Products (San Diego, CA, USA).
Cell lines and cell culture
Three HNSCC cell lines – OC3 (established from an oral 
squamous cell carcinoma [OSCC] in a long-term areca [betel] 
chewer who does not smoke), OEC-M1 (derived from gin-
gival epidermal carcinoma), and FaDu (a human pharyngeal 
squamous cell carcinoma) – were used in the experiments. It 
should be noted that OC3 and OEC-M1 cells are indigenous 
oral cavity cancer cell lines in Taiwan.20 OC3 cells were 
maintained in DMEM in addition to a twofold volume of 
keratinocyte-SFM mixed medium supplemented with 24 mM 
of NaHCO
3
, 25 mM of HEPES, 100 ppm of penicillin, 100 
ppm of streptomycin, and 10% v/v heat-inactivated fetal bovine 
serum; pH7.4. OEC-M1 cells were maintained in Roswell Park 
 Memorial Institute 1640 medium supplemented with 24 mM of 
NaHCO
3
, 25 mM of HEPES, 10,000 U of penicillin, 10,000 U 
of streptomycin, and 10% heat-inactivated fetal bovine serum; 
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and pH 7.421 FaDu cells were cultured in high-glucose DMEM 
supplemented with 10% fetal bovine serum and 0.1%  penicillin/
streptomycin. Cells were incubated in a humidified atmosphere 
containing 95% air and 5% CO
2
 at 37°C.20,21
MTT cell viability test
An MTT assay was employed to determine cell viability 
with the treatment of cordycepin and/or cisplatin. OC3 and 
OEC-M1 cells were seeded in a 96-well plate (Techno Plastic 
Products AG, Trasadingen, Switzerland) with 1 × 104 cells 
in 100 µL of serum medium among each well, and FaDu 
cells were seeded in a 96-well plate with 8 × 103 cells in 
100 µL of serum medium among each well. After reaching 
70%–80% confluence, cells were treated without or with 
cordycepin, cisplatin, or both agents in various combinations 
of concentrations (10 µM, 100 µM, or 1 mM of cordycepin 
alone; 30 µM, 300 µM, or 600 µM of cisplatin alone; and 
300 µM or 600 µM of cisplatin combined with 100 µM of 
cordycepin, respectively, for 24 hours). MTT was added 
with a final concentration of 0.5 mg/mL, and then incubated 
for 4 hours at 37°C. The medium was removed and DMSO 
(50 µL) was added into each well to dissolve the crystals 
by gently shaking the plate for 20 minutes in the dark. The 
absorbance (optical density) values in each treatment were 
then determined at λ = 590 nm by an enzyme-linked immu-
nosorbent assay microplate reader (VersaMax, Nordion, 
Ottawa, ON, Canada).
Morphological study
OC3 and OEC-M1 cells were seeded at a concentration of 
6 × 105 cells and FaDu cells were seeded at a concentration 
of 4.5 × 105 cells in a 6 cm Petri dish (Techno Plastic Prod-
ucts AG) supplemented with 2 mL of serum medium. After 
reaching 70%–80% confluence, cells were treated without or 
with 100 µM cordycepin, 300 µM cisplatin, 600 µM cisplatin, 
or 100 µM cordycepin combined with 300 µM or 600 µM 
cisplatin for 24 hours, respectively. Cell morphology was 
then observed and recorded under light microscopy (Olympus 
CK40; Olympus Corporation, Tokyo, Japan).
Flow cytometry analysis
In order to investigate whether cordycepin and/or cisplatin 
could induce cell apoptosis, flow cytometric analysis was 
used with PI stain to determine both DNA fragmentation and 
the redistribution of the cell cycle. OC3 and OEC-M1 cells 
were seeded in a 6 cm Petri dish with 2 mL of serum medium, 
which contained 6 × 105 cells, while FaDu cells were seeded 
at a concentration of 4.5 × 105 cells. After reaching 70%–80% 
confluence, cells were treated with or without 100 µM of 
cordycepin only; 300 µM or 600 µM of cisplatin only; or 
100 µM of cordycepin combined with 300 µM or 600 µM 
of cisplatin for 24 hours, respectively. The treated cells were 
harvested with trypsin, washed with phosphate buffered 
saline (PBS), and fixed in 75% ethanol for at least 2 hours 
at -20°C. After fixation, cells were washed in cold PBS and 
then collected by centrifugation and stained with PI solution 
(40 µg/mL of PI and 100 µg/mL of ribonuclease in PBS). The 
stained cells were analyzed using a fluorescence activated 
cell sorter (FACScanTM; BD Biosciences, San Jose, CA, 
USA) at λ = 488 nm and analyzed by CellQuestTM software 
(BD Biosciences). The DNA content distribution of normal 
growing cells is characterized by two peaks phenomenon; 
G1/G0 and G2/M phases. The G1/G0 phase indicates that 
cells are arrested at the resting state of the cell cycle with 
the most diploid DNA content, while cell DNA content in 
the G2/M phase increases as a consequence of progressing 
in cell cycle. Cells in the subG1 phase have the least amount 
of DNA content in the cell cycle distribution, which is called 
hypodiploid. The hypodiploid DNA content represents the 
fragmentation of DNA, indicating cell apoptosis.17
Immunoblotting analysis
Cells were lysed and protein extraction was performed. 
Protein concentration of the cell lysates was determined 
by the Lowry et al method.22 Cell proteins (30 µg) were 
separated in 12% of SDS-polyacrylamide gel, which per-
formed at 100 V for 2 hours using a standard running buf-
fer (24 mM Tris-HCl, 0.19 M glycine, 0.5% SDS, pH8.3), 
and the proteins were electrophoretically transferred to a 
polyvinylidene difluoride membrane at 400 mA for 2 hours 
in transfer buffer (20 mM Tris-HCl, 150 mM glycine, 10% 
methanol, and 0.01% SDS). The membranes were blocked 
with 4% nonfat milk, washed, and subsequently incubated 
with a specific antibody. After washing, the membrane was 
incubated with horseradish peroxidase-conjugated goat 
antimouse antibody or goat antirabbit antibody, and then 
visualized by an enhanced chemiluminescence detection kit 
(Amersham-Pharmacia International PLC, Amersham, UK). 
The optical density of each protein band was quantitated 
using a computer-assisted image analysis system (Quantity 
One, Huntington Station, NY, USA).23 The amount of β-actin 
(43 kDa) in each lane was also detected as a control.
Statistics
Each data point of the bar in the figures represents the mean ± 
standard error of the mean of three separate experiments. 
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Statistically significant differences between treatments and 
controls were determined by one-way analysis of variance, 
and then Tukey’s test was used for post hoc testing. Statistical 
significance was set at P,0.05.
Results
Effect of cordycepin and/or cisplatin  
on morphological change in HNSCC  
cell lines
OC3, OEC-M1, and FaDu cells were treated with 100 µM 
of cordycepin only; 300 µM or 600 µM of cisplatin only; or 
100 µM of cordycepin combined with 300 µM or 600 µM 
of  cisplatin for 24 hours, respectively, and morphological 
changes related to cell death were examined under light 
microscopy. Among the three cell lines, cells in the control 
and 0.5% DMSO treatments showed a polygonal shape with 
a healthy appearance, which is a normal cell growth phenom-
enon (Figure 1Aa, Ab, Ba, Bb, Ca, and Cb).  Twenty-four 
hours after treatment with 100 µM of cordycepin and 300 µM 
of cisplatin, cells appeared to be rounded-up, but they still 
adhered to the ground matrix (Figure 1Ac, Ad, Bc, Bd, Cc, 
and Cd). After 24 hours of treatment with 600 µM of cispla-
tin, many cells rounded up, with some floating in medium 
(Figure 1Ae, Be, and Ce). A combination of 100 µM of 
cordycepin plus 300 µM or 600 µM of cisplatin treatments 
Figure 1 Effect of cordycepin and/or cisplatin on morphological change in HNSCC cell lines. 
Notes: Three oral cavity cancer cell lines ([A] OC3; [B] OEC-M1; and [C] FaDu) were treated in plain medium (a), medium with DMSO (0.5%) (b), medium with 100 µM 
cordycepin (c), medium with 300 µM cisplatin (d), medium with 600 µM cisplatin (e), medium with 100 µM cordycepin plus 300 µM cisplatin (f), and medium with 100 µM 
cordycepin plus 600 µM cisplatin (g) for 24 hours. Morphological changes of cells were examined under light microscopy (bar: 0.1 mm; arrow: rounded cells). Round-up cells 
were readily observed and are indicated by the arrows. Experiments were performed three times with similar results. 
Abbreviations: HNSCC, head and neck squamous cell carcinoma; DMSO, dimethyltetrazolium bromide.
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for 24 hours resulted in a greater loss of cell attachment to 
ground matrix, more appearance of membrane blebbings, 
and more floating cells (Figure 1Af,  Ag, Bf, Bg, Cf, and 
Cg). These phenomena suggested that a combination of 
cordycepin plus cisplatin treatments induced apoptotic cell 
death in all three cell lines, which was more effective than 
cordycepin or cisplatin alone.
Effects of cordycepin and/or cisplatin  
on cell viability in HNSCC cell lines
HNSCC cell morphological changes suggested that cordyce-
pin and/or cisplatin might be involved in cell death. The MTT 
viability test was used to further examine cell viability. In 
the OC3 cell line, the cell survival rate with a treatment of 
100 µM of cordycepin alone was 77%; 300 µM or 600 µM 
of cisplatin alone showed cell survival rates of 82% and 
65%, respectively; and cordycepin (100 µM) plus cisplatin 
(300 µM or 600 µM) showed cell survival rates of 52% and 
58%, respectively, which demonstrated that the cordycepin 
plus cisplatin cotreatment could significantly reduce the cell 
survival rate (Figure 2A) (P,0.05). In fact, the cordycepin 
(100 µM) plus cisplatin (600 µM) treatment illustrated a 
synergistic cell death phenomenon (Figure 2A). In the OEC-
M1 cell line, the cell survival rate with a treatment of 100 
µM of cordycepin alone was 59%; the cell survival rates 
with 300 µM or 600 µM of cisplatin alone were 77% and 
25%, respectively; and cell survival rates with cordycepin 
(100 µM) plus cisplatin (300 µM or 600 µM) were 45% 
and 28%, respectively, which demonstrated that the com-
bination of cordycepin (100 µM) plus cisplatin (300 µM) 
could significantly reduce the cell survival rate (Figure 2B) 
(P,0.05). In the FaDu cell line, the cell survival rate with 
the 100 µM of cordycepin treatment alone was 68%; the 
cell survival rates with 300 µM or 600 µM of cisplatin 
alone were 74% and 50%, respectively; and the cell survival 
rates with the cordycepin (100 µM) plus cisplatin (300 µM 
or 600 µM) treatments were 45% and 23%, respectively, 
which demonstrated that the combination of cisplatin plus 
cordycepin could significantly reduce the cell survival rate 
(Figure 2C) (P,0.05).
Effects of cordycepin and/or cisplatin  
on cell cycle in HNSCC cell lines
To further investigate whether cordycepin and/or cisplatin 
could induce apoptosis, OC3, OEC-M1, and FaDu cells 
were examined by flow cytometry analysis to determine 
whether DNA fragmentation occurred, and whether there 
was any change in cell cycle progression. Distribution of 
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Figure 2 Effects of cordycepin and/or cisplatin on cell viability in HNSCC cell lines. 
Notes: Cells (1 × 104 cells/well for OC3 and OEC-M1; 8 × 103 cells/well for FaDu) 
were treated with plain medium, medium with DMSO (0.5%), cordycepin alone 
(10 µM, 100 µM, and 1 mM), cisplatin alone (100 µM, 300 µM, 600 µM, and 1 mM) or 
cotreatment with cordycepin (100 µM) plus cisplatin (300 and 600 µM, respectively) 
for 24 hours ([A] OC3; [B] OEC-M1; and [C] FaDu). Cell viability was quantified by 
MTT assay. Results are expressed as percentages of cell growth relative to the initial 
number of viable cells in controls (as 100%). Data represent the mean ± standard 
error of the mean of three separate experiments. *Significant difference from the 
control (plain medium) (P,0.05). 
Abbreviations: DMSO, dimethyltetrazolium bromide; HNSCC, head and neck 
squamous cell carcinoma; MTT, methylthiazoletetrazolium.
the subG1, G1, and G2/M phase cells among the OC3, 
OEC-M1, and FaDu cells with different treatments were 
illustrated in  Figure 3A–C, respectively. The results showed 
that cordycepin (100 µM) plus cisplatin (300 µM or 600 µM) 
could notably induce more subG1 phase cells among the 
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C
Figure 3 The analysis of cell cycle under cordycepin and/or cisplatin influence in HNSCC cell lines. 
Notes: The histogram plots of flow cytometry analysis in three oral cavity cancer cells ([A] OC3; [B] OEC-M1; and [C] FaDu) treated in plain medium, medium with DMSO 
(0.5%), medium with 100 µM cordycepin, medium with 300 µM cisplatin, medium with 600 µM cisplatin, medium with 100 µM cordycepin plus 300 µM cisplatin, and medium 
with 100 µM cordycepin plus 600 µM cisplatin for 24 hours were illustrated. After the treatments, cells were fixed, stained with propidium iodide, and analyzed for cell cycle 
progression by flow cytometry. The subG1 phase refers to cells that have less DNA content than normal cells, indicating apoptosis. Experiments were performed three times 
with similar results (Control represents control as plain medium). Arrow heads indicate the increase of the subg1 phase. 
Abbreviations: DMSO, dimethyltetrazolium bromide; HNSCC, head and neck squamous cell carcinoma; DNA, deoxyribonucleic acid.
three cell lines (Figure 3A–C). In order to elucidate the 
changes of the subG1, G1, and G2/M phase cells between 
different treatments, the cell number percentage among 
the OC3, OEC-M1, and FaDu cells from Figure 3A–C 
were statistically analyzed and illustrated in Figure 4A–C, 
respectively.
The percentage of subG1 phase cells in the control 
groups was 5% in the OC3 cells (Figure 4Aa), 2% in the 
OEC-M1 cells (Figure 4Ba), and 1% in the FaDu cells 
 (Figure 4Ca), respectively. Cordycepin (100 µM) induced 
subG1 phase cells to 12% in the OC3 cells (Figure 4Aa), 
11% in the OEC-M1 cells (Figure 4Ba), and 5% in the FaDu 
cells (Figure 4Ca), respectively. In treatment with cisplatin 
alone, 300 µM of cisplatin induced the subG1 phase cells to 
5% in the OC3 cells (Figure 4Aa), 10% in the OEC-M1 cells 
(Figure 4Ba), and 2% in the FaDu cells (Figure 4Ca), 
 respectively. However, 600 µM of cisplatin induced the 
subG1 phase cells to 52% in the OC3 cells  (Figure 4Aa), 
23% in the OEC-M1 cells (Figure 4Ba), and 15% in the FaDu 
cells  (Figure 4Ca), respectively.  Interestingly, cordycepin 
(100 µM) plus cisplatin (300 µM) or cordycepin (100 µM) 
plus cisplatin (600 µM)  cotreatments induced the subG1 
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phase cells to 27% and 73% in the OC3 cells (Figure 4Aa), 
17% and 24% in the OEC-M1 cells (Figure 4Ba), and 23% 
and 14% in the FaDu cells (Figure 4Ca), respectively. These 
data illustrated that cordycepin plus cisplatin cotreatments 
had a better apoptotic effect in the subG1 phase among 
the three cell lines. It should be noted that cordycepin 
plus cisplatin (300 µM or 600 µM, respectively) in the 
OC3 cells and cordycepin plus cisplatin (300 µM) in the 
FaDu cells did demonstrate a much better apoptotic effect 
in the subG1 phase.
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Figure 4 Quantification and analysis in percentage among subG1, G1, and G2/M phase cell number in HNSCC cell lines. 
Notes: The statistical analysis from three independent experiments of Figure 3 regarding the change of the cell cycle in terms of percentages of subg1, g1, and g2/M 
phases was analyzed and illustrated ([A] OC3 cells; [B] OEC-M1 cells; and [C] FaDu cells). (a) subg1 phase; (b) g1 phase; and (c) g2/M phase. Data represent the mean ± 
standard error of the mean of three separate experiments. *Significant difference when compared with controls (plain medium) in each cell cycle phase (P,0.05) (Control 
represents control as plain medium). 
Abbreviations: HNSCC, head and neck squamous cell carcinoma; DMSO, dimethyltetrazolium bromide.
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Effects of cordycepin and/or cisplatin  
on caspase pathway in HNSCC cell lines
Previous results illustrated that cordycepin and/or cisplatin 
would cause cell apoptosis among OC3, OEC-M1, and FaDu 
cells. Thus, the expressions of cleavage caspase and PARP 
proteins were investigated.
The expression of caspase-8 cleavage in the three cell 
lines under control and DMSO treatments was very low, 
and was slightly increased by treatment with cordycepin 
or cisplatin alone (300 µM or 600 µM, respectively) from 
6 hours to 36 hours. However, cordycepin plus cisplatin 
cotreatment significantly induced more caspase-8 cleavage 
between 6 hours to 24 hours among OC3, OEC-M1, and 
FaDu cells (Figures 5A, B, 6A, B, 7A and B) (P,0.05). 
The expression of cleavage caspase-9 in the three cell lines 
under the control and DMSO treatments was low, and it 
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Figure 5 Effects of cordycepin and/or cisplatin on caspase-8, caspase-9, caspase-3, and PARP protein expressions in OC3 cells. 
Notes: Cells (6 × 105 cells/well for OC3) were treated with plain medium, medium with DMSO (0.5%), medium with 100 µM cordycepin, medium with 300 µM cisplatin, 
medium with 600 µM cisplatin, medium with 100 µM cordycepin plus 300 µM cisplatin, and medium with 100 µM cordycepin plus 600 µM cisplatin for 6 hours, 12 hours, 
24 hours, and 36 hours, respectively. Cleavage caspase-8- (43 kDa), cleavage caspase-9- (35 kDa), cleavage caspase-3- (16 kDa), and cleavage PARP- (89 kDa) specific 
bands were detected by Western blot. (A) Immunoblots represent the observations from one single experiment repeated three times. The integrated optical densities of 
(B) cleaved caspase-8, (C) caspase-9, (D) caspase-3, and (E) PARP proteins were analyzed after normalization with β-actin (43 kDa) in each lane. Data in (B–E) represent 
the mean ± standard error of the mean of three separate experiments. *Statistical difference when compared to the control group (P,0.05). 
Abbreviations: DMSO, dimethyltetrazolium bromide; PARP, poly adenosine diphosphate-ribose polymerase.
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Figure 6 Effects of cordycepin and/or cisplatin on caspase-8, caspase-9, caspase-3, and PARP protein expressions in OEC-M1 cells. 
Notes: Cells (6 × 105 cells/well for OEC-M1) were treated with plain medium, medium with DMSO (0.5%), medium with 100 µM cordycepin, medium with 300 µM cisplatin, 
medium with 600 µM cisplatin, medium with 100 µM cordycepin plus 300 µM cisplatin, and medium with 100 µM cordycepin plus 600 µM cisplatin for 6 hours, 12 hours, 
24 hours, and 36 hours, respectively. Cleavage caspase-8- (43 kDa), cleavage caspase-9- (35 kDa), cleavage caspase-3- (16 kDa), and cleavage PARP- (89 kDa) specific 
bands were detected by Western blot. (A) Immunoblots represent the observations from one single experiment repeated three times. The integrated optical densities of 
(B) cleaved caspase-8, (C) caspase-9, (D) caspase-3, and (E) PARP proteins were analyzed after normalization with β-actin (43 kDa) in each lane. Data in (B–E) represent 
the mean ± standard error of the mean of three separate experiments. *Statistical difference when compared to the control group (P,0.05). 
Abbreviations: DMSO, dimethyltetrazolium bromide; PARP, poly adenosine diphosphate-ribose polymerase.
was slightly increased by treatment with cordycepin or 
cisplatin alone (300 µM or 600 µM, respectively) from 
6 hours to 24 hours. However, the cordycepin plus cisplatin 
cotreatment significantly induced more caspase-9 cleavage 
between 6 hours to 24 hours among OC3, OEC-M1, and 
FaDu cells (Figures 5A, C, 6A, C, 7A and C) (P,0.05). In 
addition, the expression of cleavage caspase-3 in these three 
cell lines under control and DMSO treatments was very low, 
and it was slightly increased by treatment with cordycepin 
or cisplatin alone (300 µM or 600 µM, respectively) from 
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6 hours to 36 hours. However, the cordycepin plus cisplatin 
 cotreatment significantly induced more caspase-3 cleav-
age between 6 hours to 12 hours in OC3 and FaDu cells 
 (Figures 5A, D, 6A, D, 7A and D) (P,0.05). Moreover, 
there was no cleavage of PARP among the three cell lines 
under control and DMSO treatments, and PARP cleavage 
slightly increased by treatment with cordycepin or cisplatin 
alone (300 µM or 600 µM, respectively) from 6 hours to 
36 hours. However, the cordycepin plus cisplatin cotreat-
ment significantly induced more PARP cleavage between 
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Figure 7 Effects of cordycepin and/or cisplatin on caspase-8, caspase-9, caspase-3, and PARP protein expressions in FaDu cells. 
Notes: Cells (4.5 × 105 cells/well for FaDu) were treated with plain medium, medium with DMSO (0.5%), medium with 100 µM cordycepin, medium with 300 µM cisplatin, 
medium with 600 µM cisplatin, medium with 100 µM cordycepin plus 300 µM cisplatin, and medium with 100 µM cordycepin plus 600 µM cisplatin for 6 hours, 12 hours, 
24 hours, and 36 hours, respectively. Cleavage caspase-8- (43 kDa), cleavage caspase-9- (35 kDa), cleavage caspase-3- (16 kDa), and cleavage PARP- (89 kDa) specific 
bands were detected by Western blot. (A) Immunoblots represent the observations from one single experiment repeated three times. The integrated optical densities of 
(B) cleaved caspase-8, (C) caspase-9, (D) caspase-3, and (E) PARP proteins were analyzed after normalization with β-actin (43 kDa) in each lane. Data in (B–E) represent 
the mean ± standard error of the mean of three separate experiments. *Statistical difference when compared to the control group (P,0.05). 
Abbreviations: DMSO, dimethyltetrazolium bromide; PARP, poly adenosine diphosphate-ribose polymerase.
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6 hours to 24 hours among OC3, OEC-M1, and FaDu cells 
(Figures 5A, E, 6A, E, 7A and E) (P,0.05). It should be 
noted that there were different levels of sensitivity among 
the caspase pathway activated by cordycepin and/or cisplatin 
between the different cell lines.
Effects of cisplatin and/or cordycepin  
on the regulation of MAPK pathway  
in HNSCC cell lines
Studies have shown that the phosphorylation of the MAPK 
pathway could either positively or negatively regulate cell 
mitosis, proliferation, and apoptosis.16,24 To determine whether 
cordycepin- and/or cisplatin-induced HNSCC cell apoptosis 
would be mediated by the MAPK pathway, the phosphoryla-
tion of JNK, ERK1/2, and p38 among the OC3, OEC-M1, and 
FaDu cells were analyzed by Western blotting.
The expression of the phosphor-JNK protein in three cell 
lines under the control and DMSO treatments was very low, 
and slightly increased by treatment with cordycepin or cispla-
tin alone (300 µM or 600 µM, respectively) from 6 hours to 
36 hours. However, the cordycepin plus cisplatin cotreatment 
significantly induced more phosphor-JNK protein between 
6 hours to 36 hours among the OC3, OEC-M1, and FaDu cells 
(Figures 8A, B, 9A, B, 10A and B) (P,0.05). In addition, the 
expression of the phosphor-ERK protein in the three cell lines 
under the control and DMSO treatments was very low, and 
slightly increased by treatment with cordycepin or cisplatin 
alone (300 µM or 600 µM, respectively) from 6 hours to 
36 hours. However, the cordycepin plus cisplatin cotreatment 
significantly induced more phosphor-ERK protein between 
6 hours to 36 hours among the OC3, OEC-M1, and FaDu cells 
(Figures 8A, C, 9A, C, 10A and C) (P,0.05).  Furthermore, 
the expression of the phosphor-p38 protein in the three cell 
lines under the control and DMSO treatments was very 
low, and slightly increased by treatment with cordycepin 
or cisplatin alone (300 µM or 600 µM, respectively) from 
6 hours to 36 hours. However, the cordycepin plus cisplatin 
cotreatment significantly induced more phosphor-p38 protein 
between 12 hours to 36 hours among the OC3, OEC-M1, and 
FaDu cells (Figures 8A, D, 9A, D, 10A and D) (P,0.05). It 
should be recognized that there were different levels of sen-
sitivity among the MAPK pathway, which were activated by 
cordycepin and/or cisplatin between the different cell lines.
Discussion
Betel quid chewing is a popular oral habit with potential links 
to the occurrence of oral cancer.25 In Taiwan, the incidence 
of oral cancer has increased in recent years.2 Cisplatin is one 
of the most well-known potent antitumor agents, displaying 
clinical activity against a wide variety of solid tumors.26 
Studies have shown that cisplatin combined with other 
anticancer drugs can enhance more cell death.6 It has been 
reported that cordycepin could effectively inhibit tumor cell 
growth concomitant with the induction of apoptotic and/or 
autophagic cell death in breast cancer cells, Leydig tumor 
cells, and oral cavity cancer cells;9,19,27 thus, the combination 
of different chemicals might be more effective in treating 
cancer cells.28 In fact, we have just reported that treatment 
with cordycepin plus cisplatin combined could cause a better 
effect of cell death in OC3 cells through a very preliminary 
mechanism investigation.29 In the present study, we used 
three oral cavity cancer cells lines (OC3, OEC-M1, and 
FaDu) to further investigate the combined apoptotic effect 
of cordycepin plus cisplatin with a detailed examination of 
the cellular mechanisms.
Our data showed that treatment with cordycepin or cispla-
tin alone induced the cell death phenomenon with the loss of 
cell attachment to the ground matrix, the appearance of mem-
brane blebbings, and floating cells. Cordycepin plus cisplatin 
cotreatments induced more cell death, which showed a greater 
effect on three HNSCC cell lines. In fact, similar results have 
been illustrated on other oral cavity cancer cell lines, and the 
same appearance induced by cisplatin can also be found on 
other tumor cells.7,28 Indeed, other studies have shown that 
many factors could activate different cellular pathways and can 
respond to enhance cisplatin antitumor effects; for instance, 
luteolin enhanced p53 stabilization and accumulation,30 and 
dexamethasone enhanced angiostatic activity and modulating 
cell cycle kinetics in different cell types.31 Our study showed 
that cordycepin could induce a greater expression of caspase 
and the MAPK protein to enhance the antitumor effect of 
cisplatin in HNSCC cells. Hence, our observations are parallel 
to those studies. Moreover, cell viability results showed that 
the cordycepin plus cisplatin cotreatment could induce more 
cell death among the three HNSCC cell lines as compared 
to cordycepin or cisplatin treatment alone, and an enhanced 
effect could be observed in the OC3 cells.  Interestingly, the 
amount of cell death among the OEC-M1 and FaDu cells 
affected by cordycepin or cisplatin was higher than in the 
OC3 cells, which demonstrated that there were different 
sensitivities among the three HNSCC cell lines to cordycepin 
and/or cisplatin. In fact, these phenomena are also found in 
other studies.32,33
In the cell cycle analysis, the percentage of subG1 
phase cells increased to 11%–12% in the OC3 and 
OEC-M1 cells after treatment with cordycepin alone, 
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Figure 8 Effects of cordycepin and/or cisplatin on the protein expression of the MAPK pathway in OC3 cells. 
Notes: Cells (6 × 105 cells/well for OC3) were treated with plain medium, medium with DMSO (0.5%), medium with 100 µM cordycepin, medium with 300 µM cisplatin, 
medium with 600 µM cisplatin, medium with 100 µM cordycepin plus 300 µM cisplatin, and medium with 100 µM cordycepin plus 600 µM cisplatin for 6 hours, 12 hours, 
24 hours, and 36 hours, respectively. P-JNK- (46, 55 kDa), P-ERK- (44, 42 kDa), and P-p38- (43 kDa) specific bands were detected by Western blot. (A) Immunoblot 
represents the observations from one single experiment repeated three times. The integrated optical densities of (B) P-JNK, (C) P-ERK1/2, and (D) P-p38 proteins were 
analyzed after normalization with the total protein in each lane. Data in (B–D) represent the mean ± standard error of the mean of three separate experiments. *Statistical 
difference when compared to the control group (P,0.05). 
Abbreviations: DMSO, dimethyltetrazolium bromide; P, phosphorylated; JNK, Jun NH2-terminal kinase; ERK, signal-regulated kinase; MAPK, mitogen-activated protein 
kinases.
which demonstrated greater efficiency than in the FaDu 
cells (only 5%). The percentage of subG1 phase cells 
significantly increased to 54% after treatment with 600 
µM of cisplatin alone in the OC3 cells, and increased to 
15%–20% in the OCE-M1 and FaDu cells, respectively. 
Exclusively, the percentage of subG1 phase cells in the 
cordycepin (100 µM) plus cisplatin (300 µM) cotreat-
ment group significantly increased in all three cell lines. 
It should be noted that cordycepin plus cisplatin (300 
µM and 600 µM, respectively) in the OC3 cells and 
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Figure 9 Effects of cordycepin and/or cisplatin on the protein expression of the MAPK pathway in OEC-M1 cells. 
Notes: Cells (6 × 105 cells/well for OEC-M1) were treated with plain medium, medium with DMSO (0.5%), medium with 100 µM cordycepin, medium with 300 µM cisplatin, 
medium with 600 µM cisplatin, medium with 100 µM cordycepin plus 300 µM cisplatin, and medium with 100 µM cordycepin plus 600 µM cisplatin for 6 hours, 12 hours, 
24 hours, and 36 hours, respectively. P-JNK- (46, 55 kDa), P-ERK- (44, 42 kDa), and P-p38- (43 kDa) specific bands were detected by Western blot. (A) Immunoblot 
represents the observations from one single experiment repeated three times. The integrated optical densities of (B) P-JNK, (C) P-ERK1/2, (D) and p-p38 proteins were 
analyzed after normalization with the total protein in each lane. Data in (B–D) represent the mean ± standard error of the mean of three separate experiments. *Statistical 
difference when compared to the control group (P,0.05). 
Abbreviations: DMSO, dimethyltetrazolium bromide; P, phosphorylated; JNK, Jun NH2-terminal kinase; ERK, signal-regulated kinase; MAPK, mitogen-activated protein 
kinases.
cordycepin plus cisplatin (300 µM) in the FaDu cells 
did demonstrate a synergistically apoptotic effect in 
the subG1 phase. In fact, the synergistic/additive effect 
of cisplatin plus other drugs has been demonstrated in 
nasopharyngeal cancer (NPC) cell lines (NPC-TW01 
and NPC-TW04), human HNSCC cell line SCC25, and 
human epidermoid carcinoma A431 cells.34,35 It has also 
been shown that a combination of different agents could 
induce more antitumor efficiency;36 thus, our findings 
are consistent with those investigations.
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Figure 10 Effects of cordycepin and/or cisplatin on the protein expression of MAPK pathway in FaDu cells. 
Notes: Cells (4.5 × 105 cells/well for FaDu) were treated with plain medium, medium with DMSO (0.5%), medium with 100 µM cordycepin, medium with 300 µM cisplatin, 
medium with 600 µM cisplatin, medium with 100 µM cordycepin plus 300 µM cisplatin, and medium with 100 µM cordycepin plus 600 µM cisplatin for 6 hours, 12 hours, 
24 hours, and 36 hours, respectively. P-JNK- (46, 55 kDa), P-ERK- (44, 42 kDa), and P-p38- (43 kDa) specific bands were detected by Western blot. (A) Immunoblot 
represents the observations from one single experiment repeated three times. The integrated optical densities of (B) P-JNK, (C) P-ERK1/2, and (D) P-p38 proteins were 
analyzed after normalization with the total protein in each lane. Data in (B–D) represent the mean ± standard error of the mean of three separate experiments. *Statistical 
difference when compared to the control group (P,0.05). 
Abbreviations: DMSO, dimethyltetrazolium bromide; P, phosphorylated; JNK, Jun NH2-terminal kinase; ERK, signal-regulated kinase; MAPK, mitogen-activated protein 
kinases.
In the present study, the cordycepin plus cisplatin cotreat-
ment significantly induced greater expressions of cleavage 
caspase-3 and PARP compared to treatment with cordycepin or 
cisplatin alone. We further investigated whether the  caspase-8 
(extrinsic) and/or caspase-9 (intrinsic) pathways would be 
 activated. Results showed that both extrinsic and intrinsic 
 caspase pathways were activated by the cordycepin plus cis-
platin cotreatment. Many studies have shown the synergistic 
effect on caspase and/or PARP protein cleavages to induce 
apoptosis among different tumor cell types.37  Therefore, our 
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results are not unprecedented. It should be noted that the bet-
ter effects in caspase-8, caspase-3, and PARP cleavages by 
cordycepin plus cisplatin cotreatment could be observed in 
OC3, but not in the OEC-M1 and FaDu cells. Also, it should be 
recognized that there are different levels of sensitivity among 
the caspase pathway activated by cordycepin and/or cisplatin 
between the OC3, OEC-M1, and FaDu cells.
In our observations, the cordycepin alone treatment 
slightly increased the expression of the MAPK proteins. 
However, cordycepin plus cisplatin induced a greater expres-
sion of phosphorylated-JNK and phosphorylated-ERK among 
the OC3, OEC-M1, and FaDu cells. The phosphorylated-p38 
could be hardly detected in the OC3 and FaDu cells, but could 
be observed in the OEC-M1 cells from 6 hours to 12 hours 
after combined treatment. A higher dosage of the combination 
showed a greater expression of phosphorylated-p38. These 
findings suggest that cordycepin and/or cisplatin could acti-
vate the phosphorylation of JNK and ERK proteins to induce 
HNSCC cell apoptosis; however, only the cordycepin plus 
cisplatin combinations could activate the phosphorylation of 
the p38 protein to induce HNSCC cell apoptosis. It should 
be noted that the greater effect of  phosphorylated-JNK, 
 phosphorylated-ERK, and phosphorylated-p38 protein 
expressions could be observed by cordycepin plus cisplatin 
(300 µM) among the OC-3, OEC-M1, and FaDu cells. Also, 
it should be noted that there were different levels of sensitivity 
among the MAPK pathway activated by cordycepin and/or 
cisplatin between the OC-3, OEC-M1, and FaDu cell lines.
Conclusion
In conclusion, cordycepin and cisplatin possess better 
apoptotic effects by activating the expression of extrinsic 
and intrinsic caspase and MAPK pathways in human oral 
cavity cancer cell lines, which highly suggests that the 
combination treatment of cordycepin and cisplatin might 
be a potential anticancer drug when compared to the single 
agent chemotherapy.
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